In 2022, Kim et al. reported that the negative expression of FcRn in non-small cell lung cancer cells is associated with significantly lower disease-free survival and decreased disease-specific survival in patients with TNM stage I disease [32]. This evidence concerns the gene FCGRT and non-small cell lung carcinoma.